Toby Talbot
Royal Cornwall Hospital Trust · 29 works · 801 citations · h-index 9
Top works
- Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
- Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
- First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study
- Ipilimumab in the real world
- SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
- A Multicentre Retrospective Analysis of Toxicity in 6-weekly Versus 3-weekly Pembrolizumab
- Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial
- Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743
- Efficacy of carboplatin–etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis
- Stratification of PD-1 blockade response in melanoma using pre- and post-treatment immunophenotyping of peripheral blood
- Service Improvements and Workload Increases: Royal College of Radiologists (RCR) Re-Audit of Curative Intent Radiotherapy for Non-Small Cell Lung Cancer (NSCLC)
- CPC06 The proof is in the ink: granulomatous tattoo reaction secondary to BRAF and MEK inhibition
- Ipilimumab in the real world: The U.K. expanded access programme (EAP) experience in advanced melanoma.
- Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study
- The burden of neutropenic sepsis in patients with advanced non-small cell lung cancer treated with single-agent docetaxel: A retrospective study
- 1129P Clinical outcomes from a tebentafusp UK expanded access program in patients with metastatic uveal melanoma (mUM)
- IPSOS: A Phase III, Global, Multicentre, Open-Label, Randomised, Controlled Study of First-Line Atezolizumab Versus Single-Agent Chemotherapy in Patients with Non-Small Cell Lung Cancer Ineligible for Treatment with a Platinum-Containing Regimen
- CODAK: Real-World Clinical Outcomes of Patients With Unresectable, Stage III Non–Small Cell Lung Cancer Treated With Durvalumab After Chemoradiotherapy in the United Kingdom
- Abstract 7147: Ultra-high throughput single-nuclei RNAs sequencing of malignant pleural mesothelioma samples in the BEAT-MESO clinical trial
- Clinically relevant recurrence of basal cell carcinoma following primary treatment with hypofractionated kilovoltage radiotherapy: a single-centre retrospective review